CVS Health (CVS) has drawn fresh attention after recent share price gains, with the stock up about 11.7% over the past week and roughly 10.4% over the past month. This has prompted closer scrutiny from investors.

Those short term gains sit within a stronger run, with a 90 day share price return of 23.11% and a 1 year total shareholder return of 56.40%, suggesting momentum has been building.

If recent gains in healthcare catch your attention, it could be a good moment to broaden your watchlist with 39 healthcare AI stocks

With CVS Health trading at US$95.93 against an average analyst price target of about US$103.04 and an indicated intrinsic discount of 68.35%, you have to ask: is this a genuine value opportunity, or is the market already baking in future growth?

Most Popular Narrative: 7.8% Undervalued

According to the most followed valuation narrative, CVS Health's fair value of about $104 sits above the last close at $95.93, which puts the current rally in a different light.

CVS Health has just faced a stock decline of about 10% after its preliminary Q3 earnings miss, which made the entire market aware. The decline is contributed largely to a $1.1 billion charge connected with its Medicare and Individual Exchange businesses and a $1.2 billion restructuring charge for store closures. The result has been increasing uncertainty, due in part to leadership changes and rising medical costs, with investors questioning whether CVS can make the shift from retail to a healthcare model. The recent drop in the stock reflects the skepticism and cautious optimism of investors as the business faces pressure to increase operating income while controlling expenses in the Health Care Benefits segment.

Want to see what sits behind that fair value estimate and restructuring story? According to yiannisz, the model leans heavily on earnings power, margin repair and a very specific path for the healthcare benefits engine and cash generation. The tension between near term cost pressure and those longer term assumptions is where the full narrative becomes more detailed.

Result: Fair Value of $104.01 (UNDERVALUED)

However, this hinges on CVS containing medical cost trends and executing its US$2b restructuring without further earnings surprises that could quickly erode investor confidence.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Multiples Flash a Different Signal

Here is the twist. While the narrative and cash flow work suggest CVS Health is undervalued, the current 41.7x P/E looks expensive against both the US Healthcare industry at 23.5x and peers at 18.3x. It also sits above a 37x fair ratio that the market could eventually lean toward.

If the share price were to move closer to that fair ratio or even the wider peer average, investors would be looking at a very different risk reward setup than the DCF style upside story implies. Which lens do you trust more right now?

Next Steps

With mixed signals on value and risk, it makes sense to move quickly and look at the underlying data yourself before forming an opinion, so take a closer look at CVS Health's 2 key rewards and 5 important warning signs

Looking for more investment ideas?

If you stop at CVS, you might miss other opportunities that fit your style, so use the screener to pressure test and upgrade your broader watchlist.

• Target higher quality at sensible prices by reviewing companies highlighted in 49 high quality undervalued stocks.
• Prioritise resilience by focusing on stocks surfaced through the 64 resilient stocks with low risk scores.
• Get ahead of the crowd by hunting for strong fundamentals via the screener containing 22 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.